SUPERNUS PHARMACEUTICALS, INC. Other Nonoperating Expense
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Other Nonoperating Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2026-03-02
- SUPERNUS PHARMACEUTICALS, INC. other nonoperating expense for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. other nonoperating expense for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. other nonoperating expense for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. other nonoperating expense for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. other nonoperating expense for fiscal 2025 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. other nonoperating expense for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. other nonoperating expense for fiscal 2023 was $2.42M, a 65.84% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. other nonoperating expense for fiscal 2022 was $7.07M, a 69.82% decline from fiscal 2021.
| Period end | Other Nonoperating Expense 3 month | Other Nonoperating Expense 6 month | Other Nonoperating Expense 9 month | Other Nonoperating Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $910.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $910.00K derived: sum of 3 quarters · filed 2026-03-02 | $2.42M 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 | $910.00K derived: sum of 2 quarters · filed 2024-08-06 | $2.42M 10-Q · filed 2023-11-08 | $4.01M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $910.00K 10-Q · filed 2024-08-06 | $2.42M 10-Q · filed 2024-08-06 | $4.01M derived: sum of 3 quarters · filed 2025-02-25 | $5.73M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $1.50M 10-Q · filed 2024-05-08 | $3.10M derived: sum of 2 quarters · filed 2025-02-25 | $4.82M derived: sum of 3 quarters · filed 2025-02-25 | $6.63M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $3.32M derived: sum of 2 quarters · filed 2025-02-25 | $5.13M derived: sum of 3 quarters · filed 2025-02-25 | $7.07M 10-K · filed 2025-02-25 |
| 2022-09-30 | $1.72M 10-Q · filed 2023-11-08 | $3.53M derived: sum of 2 quarters · filed 2023-11-08 | $5.48M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $1.81M 10-Q · filed 2023-08-08 | $3.75M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $1.94M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $23.42M 10-K · filed 2023-03-09 | |||
| 2020-12-31 | $23.75M 10-K · filed 2023-03-09 | |||
| 2020-03-31 | $5.75M 10-Q · filed 2020-05-15 | |||
| 2019-12-31 | $22.71M 10-K · filed 2022-04-13 | |||
| 2019-03-31 | $5.87M 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | $18.11M 10-K · filed 2021-03-08 | |||
| 2017-12-31 | $1.57M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |